Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: Shake-Man who wrote (265)	3/21/1998 7:41:00 AM
From: Tenpoint	Read Replies (2) \| Respond to of 384

Nobody is going to do a thing about MYL's pricing policies. What can they do especially if the new prices are still 50% below the branded drug. Hopefully the pharmacist will be able to make alittle more money when they dispense generics. Remember Mylan's total revenue this past quarter was 129 million compare that to any of the other big branded drug companies. I can't find any reason to sell this stock based on the fundamentals. Can anybody tell me a reason to sell this stock at this time?